Behind every paper at The Lancet Group are layers of editorial scrutiny and integrity checks.
✅ Learn how we work with authors and teams around the world to support trustworthy research: spkl.io/6332576U3b
New Research
Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia
www.thelancet.com/journals/lan...
New Online!
A timely Correspondence on the potential under-detection of clinically significant #hantavirus cases in #Argentina.
Authors estimate 292 clinically significant cases under the baseline scenario, compared with 90 officially reported.
www.thelancet.com/journals/lan...
New Research
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
www.thelancet.com/journals/lan...
News Piece
Update on the Ebola virus outbreak in DR Congo
www.thelancet.com/journals/lan...
New research
Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial
www.thelancet.com/journals/lan...
New Correspondence
Estimation of the Ebola outbreak size in the Democratic Republic of the Congo
www.thelancet.com/journals/lan...
New research article
Widespread circulation of #Alongshan virus in Austria and serological evidence for infection in humans: a nationwide molecular and serological observational study
www.thelancet.com/journals/lan...
#IDSky #ClinMicro #ViroSky #flavivirus #OpenAccess #OA
New comment
Can better oral care reduce non-ventilator hospital-acquired pneumonia?
www.thelancet.com/journals/lan...
This multicentre randomised controlled trial demonstrates that improving oral care
reduces NV-HAP incidence among hospitalised patients, compared with usual care. Our
findings provide novel and clinic...
In both VACV-naive and VACV-experienced participants, BNT166a was well tolerated,
with local and systemic reactogenicity events occurring more frequently after the
second dose than the first. BNT166a ...
As of June 8, 2026, authorities in DR Congo are struggling to contain an outbreak
of Ebola virus disease due to Bundibugyo virus, with 598 confirmed cases and 115 deaths.
Talha Burki reports.
www.thelancet.com
Yellow fever booster vaccination was safe and immunogenic in healthy Gambian children.
Protective neutralising antibody waned following primary vaccination and boosting
had a more pronounced effect in...
The ongoing outbreak of Bundibugyo virus disease, a form of Ebola virus disease caused
by the Bundibugyo virus, in the Democratic Republic of the Congo is evolving rapidly.
As of May 27, 2026, 1031 su...
✨ NEW EPISODE ✨ #ScienceInContext This week Dr @eonore.bsky.social speaks with Dr Ruth McCabe about the current #Ebola outbreak & collaboration with @who.int & regional health authorities estimating the outbreak size published in @thelancetinfdis.bsky.social - one to watch!
youtu.be/x-V6lYG7HvE
Non-ventilator hospital-acquired pneumonia (NV-HAP) is the most frequent and deadly
health-care-associated infection.1,2 The Hospital Acquired Pneumonia Prevention (HAPPEN)
trial, presented by Nicole ...
